
Results
7
Companies which are more than 50% undervalued based on analyst price target.
7 companies
Caliway Biopharmaceuticals
Market Cap: NT$161.9b
Engages in the development of drugs for aesthetic medicine and chronic inflammation.
6919
NT$104.00
7D
-5.0%
1Y
-20.9%
Bora Pharmaceuticals
Market Cap: NT$53.9b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$423.00
7D
-1.3%
1Y
-39.1%
Lotus Pharmaceutical
Market Cap: NT$50.6b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$192.50
7D
-4.9%
1Y
-12.9%
Oneness Biotech
Market Cap: NT$22.9b
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan.
4743
NT$47.70
7D
-5.9%
1Y
-27.1%
TaiMed Biologics
Market Cap: NT$16.0b
A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases.
4147
NT$58.40
7D
-10.6%
1Y
-29.3%
Medigen Vaccine Biologics
Market Cap: NT$15.6b
A biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
6547
NT$47.55
7D
-0.5%
1Y
13.5%
Foresee Pharmaceuticals
Market Cap: NT$13.1b
Operates as biopharmaceutical company in the United States, China, and Europe.
6576
NT$83.00
7D
1.6%
1Y
13.7%